731. Pharmacokinetics of Gepotidacin (GSK2140944) in Subjects with Hepatic Impairment

BACKGROUND: Gepotidacin (GEP), a first in class novel triazaacenaphthylene bacterial topoisomerase inhibitor, inhibits bacterial replication and has in vitro and in vivo efficacy activity against key pathogens, including drug-resistant strains, associated with a range of infections. In a previous ab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Hands, Jonathan T, Tao, Yu, Tiffany, Courtney, Perry, Caroline R, Dumont, Etienne, Hossain, Mohammad
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810886/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.799
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados